LUX-lung 4: A phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3335-3342

  Katakami, Nobuyuki ^a   Atagi, Shinji ^b   Goto, Koichi ^e   Hida, Toyoaki ^f   Horai, Takeshi ^g   Inoue, Akira ^h   Ichinose, Yukito ⁱ   Koboyashi, Kunihiko ^j   Takeda, Koji ^c   Kiura, Katsuyuki ^k   Nishio, Kazuto ^d   Seki, Yoko ^l   Ebisawa, Ryuichi ^l   Shahidi, Mehdi ⁿ   Yamamoto, Nobuyuki ^m  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h TOHOKU UNIVERSITY HOSPITAL   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^k OKAYAMA UNIVERSITY   (Japan)

^l NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^m SHIZUOKA CANCER CENTER   (Japan)

ⁿ BOEHRINGER INGELHEIM LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ERLOTINIB; GEFITINIB;

ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; EPISTAXIS; EXON; EYE DISEASE; FATIGUE; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; INFLAMMATION; JAPANESE; LIP DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RHINOPHARYNGITIS; STOMATITIS; TREATMENT RESPONSE; VERY ELDERLY; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 84884618137     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0981     Document Type: Article

References (29)

1. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005. (Pubitemid 40425952)
2. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
3. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010.
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380- 2388, 2010.
5. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011.
6. Ku GY, Haaland BA, de Lima Lopes G Jr: Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Metaanalysis of phase III trials. Lung Cancer 74:469- 473, 2011.
7. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012.
8. Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-5769, 2006. (Pubitemid 44629607)
9. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501, 2006. (Pubitemid 44799723)
10. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711, 2008.
11. Solca F, Dahl G, Zoephel A, et al: Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350, 2012.
12. Yap TA, Vidal L, Adam J, et al: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972, 2010.
13. Murakami H, Tamura T, Takahashi T, et al: Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUXLung 4). Cancer Chemother Pharmacol 69:891-899, 2012.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000.
15. Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28:357-360, 2010.
16. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774, 2010.
17. Pietanza MC, Lynch TJ Jr, Lara PN Jr, et al: XL647: A multitargeted tyrosine kinase inhibitor- Results of a phase II study in subjects with nonsmall cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 7:219-226, 2012.
18. Johnson ML, Riely GJ, Rizvi NA, et al: Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol 6:1128-1131, 2011.
19. Janjigian YY, Azzoli CG, Krug LM, et al: Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 17:2521-2527, 2011.
20. Sequist LV, Besse B, Lynch TJ, et al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083, 2010.
21. Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 13:528-538, 2012.
22. Riely GJ, Kris MG, Zhao B, et al: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155, 2007. (Pubitemid 47502083)
23. Workman P, Clarke PA: Resisting targeted therapy: Fifty ways to leave your EGFR. Cancer Cell 19:437-440, 2011.
24. Yang JC, Shih JY, Su WC, et al: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 13:539-548, 2012.
25. Lee J, Park K, Kim S-W: A randomized phase III study of gefinitib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a firstline treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. Presented at the 13th World Conference on Lung Cancer, San Francisco, CA, July 31-Aug 4, 2009.
26. Regales L, Gong Y, Shen R, et al: Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010, 2009.
27. Horn L, Groen H, Smit E, et al: Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M- NSCLC patients. Presented at the 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011 (abstr O19.07).
28. Janjigian Y, Groen H, Horn L: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29:482s, 2011 (suppl; abstr 7525).
29. Yang JC-H, Schuler MH, Yamamoto N, et al: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30:480s, 2012 (suppl; abstr LBA7500).